Deterioration of headache impact and health-related quality of life in migraine patients after cessa...
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
About this item
Full title
Author / Creator
Publisher
Milan: Springer Milan
Journal title
Language
English
Formats
Publication information
Publisher
Milan: Springer Milan
Subjects
More information
Scope and Contents
Contents
Background
Migraine preventive treatment with CGRP(−receptor) monoclonal antibodies (mAbs) has a positive effect on patients’ health-related quality of life (HRQoL). The German treatment guidelines recommend discontinuing successful treatment with CGRP(−receptor) mAbs after 6–12 months. We aimed to evaluate headache-specific and generic HRQoL fo...
Alternative Titles
Full title
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3661b867a0f347c0af2826ef208d9863
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3661b867a0f347c0af2826ef208d9863
Other Identifiers
ISSN
1129-2369
E-ISSN
1129-2377
DOI
10.1186/s10194-021-01368-7
